Compare Neurocrine Biosciences Inc (NBIX) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Invesco WilderHill Clean Energy ETF trades at $28.29 (market cap $347.46M). The key difference: Neurocrine Biosciences Inc is far larger — about 42× Invesco WilderHill Clean Energy ETF's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Invesco WilderHill Clean Energy ETF for 46 Days on average.
| NBIX | PBW | |
|---|---|---|
Market Cap | $14.60B | $347.46M |
Volume | 1,075,694 | 413,698 |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $46.99 |
52-Week Low | $123.10 | $28.29 |
Typical Hold Time | 23 Days | 46 Days |
Enterprise Value | $14.61B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
PBW, the Invesco WilderHill Clean Energy ETF, trades at $28.92, down 2.89% today amid a bearish technical signal from moving averages. The ETF's unique selection criteria prioritize ecological factors over financial metrics, resulting in concentrated exposure to the clean energy sector. Recent institutional selling, including a 96.3% reduction by IFP Advisors Inc. in Q2 2026 (SEC filing, September 18, 2026), reflects cautious sentiment despite long-term growth drivers like energy security and data center demand.
Outlook remains challenged by near-term volatility and sector underperformance versus broad markets, though global investment in clean energy offers structural tailwinds. Key risks include oil price swings, Fed policy impacts, and lack of diversification. Investors face a trade-off between speculative growth potential and elevated sensitivity to macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
